Glenmark Pharma arm enters $1.1 billion agreement with Hengrui for oncology drug
As part of the agreement, Glenmark will make an upfront payment of $18 million to Hengrui. The latter is also eligible to receive regulatory and commercial milestone payments of up to $1.093 billion. Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,021.70, up by ₹3.40, or 0.17%, on the BSE.

What's Your Reaction?






